Macrogenics Inc Stock Price, News & Analysis

MacroGenics, Inc. (MGNX) has launched a Phase 1 dose escalation study of MGC018 in combination with lorigerlimab, focusing on B7-H3-directed therapies for treating solid tumors. The company plans to meet the FDA to discuss a registration-directed study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC). Financially, MacroGenics reported $77.4 million in revenue for 2021, a decline from $104.9 million in 2020. The net loss widened to $202.1 million, compared to $129.7 million in the previous year. The company maintains a cash runway through 2023.

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:

• Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
• Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
• 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.

Archived webcasts will be available on MacroGenics' website.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several healthcare conferences in November and December 2021. Key events include:

• Credit Suisse 30th Annual Healthcare Conference: November 9, 2021, at 8:00 am ET.
• Stifel 2021 Virtual Healthcare Conference: November 16, 2021, at 8:00 am ET.
• Evercore ISI HealthCONx Virtual Conference: December 2, 2021, at 8:25 am ET.
• JMP Securities Hematology and Oncology Summit: December 6, 2021, at 1:00 pm ET.

Webcasts of these presentations will be available on their website.

MacroGenics, Inc. (NASDAQ: MGNX) has submitted an IND application for MGD024, a bispecific DART molecule targeting CD123 and CD3 for AML. The FDA approved its GMP manufacturing facility for MARGENZA drug substance. However, enrollment for Cohort A of the Phase 2/3 MAHOGANY study of margetuximab is being discontinued. Financial results for Q3 2021 revealed total revenue of $15.7 million, down from $18.3 million in Q3 2020. R&D expenses rose to $49.8 million, leading to a net loss of $52.9 million. The company expects its cash position to fund operations through 2023.

MacroGenics, Inc. (Nasdaq: MGNX) will release its third-quarter 2021 financial results after the market closes on November 2, 2021. A conference call to discuss these results and recent corporate developments will be held on the same date at 4:30 pm ET. Investors can join the call by dialing the appropriate access numbers five minutes prior to the start. The presentation will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days post-call.

MacroGenics announced promising interim results from Part 1 of the Phase 2/3 MAHOGANY clinical trial for margetuximab, targeting HER2+ gastric cancer. Out of 40 evaluated patients, 21 achieved confirmed responses, exceeding the trial's futility boundaries. The combination therapy demonstrated a 78% tumor shrinkage rate and a median response duration of 10.3 months. The treatment was well tolerated, with only 19% experiencing Grade 3 adverse events. These findings support advancing to Part 2 of the trial, with potential implications for first-line treatment options.

MacroGenics (NASDAQ: MGNX) announced preliminary safety and anti-tumor results from the Phase 1 trial of MGC018, an investigational antibody-drug conjugate. In metastatic castration-resistant prostate cancer (mCRPC), 54% of patients showed ≥ 50% PSA reduction, while 63% of evaluable patients displayed anti-tumor activity. In non-small cell lung cancer (NSCLC), 81% of evaluable patients had anti-tumor activity. The treatment demonstrated a manageable safety profile with only 7% discontinuation due to treatment-related adverse events. Further updates on other cohorts are anticipated.

On September 12, 2021, MacroGenics (Nasdaq: MGNX) announced multiple poster presentations for its investigational product candidates at the ESMO Virtual Conference scheduled for September 16-21, 2021. Key presentations include preliminary results for MGC018, an antibody-drug conjugate targeting advanced solid tumors, and data from the MAHOGANY trial on margetuximab in HER2+, PD-L1+ gastroesophageal adenocarcinoma. The posters will be accessible on the ESMO website and MacroGenics' investor relations page.